A new cancer treatment that uses nanotechnology has shown “astounding” results in mice.
Scientists believe technique could offer treatment for metastatic cancer of lungs and liver after successful tests on mice.
Scientists believe the technique could offer a treatment for metastatic cancer of the lungs and liver, two of the main causes of death for patients with a wide range of incurable cancers that have spread around the body.
The researchers developed a method of delivering anti-cancer drugs to these vital organs using a “nanoparticle generator” that can bypass a tumour cell’s ability to develop drug resistance.
Tests on mice with incurable breast cancer that has spread to the lungs shows that half of them were effectively cured of the disease after eight months of follow-up – equivalent to 24 years of long-term survival in humans.
If the finding were to be replicated by other researchers, it would represent a new milestone in cancertherapy, coming just weeks after breakthroughs in cancer immunology where the body’s own immune defences were shown to be capable of launching an attack on spreading tumours.
The latest treatment is based on injecting the patient with a porous silicon material that has been absorbed with an anti-cancer drug. After injection into the blood stream, the material is carried to the site of a tumour where the silicon breaks down to produce cancer-killing nanoparticles.
Mauro Ferrari, the scientist who led the work at the Houston Methodist Research Institute in Texas, said that the results on mice are unprecedented and clinical trials on the first human patients could begin as early as next year, using a “nanoparticle generator” to improve the potency of existing anti-cancer drugs.
“To my very best understanding, this is the first case we’ve ever seen of a therapy with a well understood mechanism that can provide long-term, disease-free survival of our pre-clinical animal populations,” Dr Ferrari said.
“If this bears out in the clinical realm, even a short fraction in the preclinical experimentation that we did, it will be transformational. It will be the first ever demonstration of a cure of metastatic disease to the lungs,” he said.
The study, published in the journal Nature Biotechnology, used a standard chemotherapy drug called doxorubicin. However, it was the drug-delivery mechanism, using nanotechnology, that produced the stunning results, he said. Nanotechnology refers to the science of extremely small things, and the approach has recently seen major breakthroughs in an array of scientific fields.
“Lung and liver metastases are the two main reasons why we lose cancer patients. The results we have proven with this paper is that we can provide a functional cure; we can essentially cure long-term, [giving] disease-free survival for about 50 per cent of the animals that we provided this therapy to,” Dr Ferrari said.
“Through understanding the mechanism we can begin to think about strategies that will work for the other 50 per cent as well,” he said.
“If this research bears out in humans and we see even a fraction of this survival time, we are still talking about dramatically extending life for many years. That’s essentially providing a cure in a patient population that is now being told there is none,” he added.
The nanoparticle generator effectively concentrates the anti-cancer drug within the tumour cells, leaving healthy cells untouched, which should avoid many of the toxic side-effect seen in patients treated conventionally. The nanoparticle polymer breaks down into single strands that curl up into nanoparticles. These are quickly absorbed by cancer cells and taken into the cell nucleus where the drug is released and the cell dies.
“This may sound like science fiction, like we’ve penetrated and destroyed the Death Star, but what we discovered is transformational. We invented a method that actually makes the nanoparticles inside the cancer and release the drug particles at the site of the cellular nucleus,” Dr Ferrari said.
“I would never want to overpromise to the thousands of cancer patients looking for a cure, but the data is astounding. We’re talking about changing the landscape of curing metastatic disease, so it’s no longer a death sentence,” he said.
RECENT LIVE STREAM SHOWS
August 28: India Online Conference: Ped Neurosurg: Subodh Raju, MD "Surgical Options in Craniosynostosis"
July 22: John Giannios MD, Precision Medicine Leader, talks about "Precision Epigenomic Medicine of Incurable Solid Tumors "
July 20: John Giannios MD, Precision Medicine Leader, talks about "Precision Cancer Medicine in the Postgenomics Era"
July 19: John Giannios MD, talks about "NANOSURGERY FOR ERADICATION OF METASTATIC CANCER STEM CELLS "
July 20: Joe Krainin MD, Neurologist, Sleep Apnea expert, talk to A Fib expert, Steve Ryan Phd, meet and discuss AFib and Sleep Apnea
July 9: Iype Cherian MD, Neurosurgery Superstar, presents "Basilar Artery Dissection, for the ACNS Online Conference
July 9: Roberto Herrera MD: Presenting Case in Online Neurosurgery Conference, a New Wave of Conferences
July 9 Ramesh Nair MD, English Neurosurgeon, Presents a Few Skull Base Cases
May 3: John Byler, noted TBI Support Advocate, talks about his book, "You Look Great"
April 20: Catherina Borgenstierna of Sweden Presents her Robotic Assisted Eating Device, Bestic
April 19: Jon Dreyer of Nuance Healthcare Communication talks about New Dragon Voice Recording Platform
John Adler MD: Stanford Neurosurgeon: Inventor of Cyberknife: "Cureus.com and Innovative Medical Publishing"
March 27 "Diving into the Rhoton Collection": Iraqui Neurosurgeons Discusses
March 27: Bernardo de Andrada MD: Brazil Neurosurgeon: "Intracranial Meningiomas"
Victor Volovici MD: Dutch Neurosurgeon: " Petrous Bone: Cave of Wonders"
March 27: Peter Galkin MD: Russian Neurosurgeon: "Saphenous Vein Greaft for CAD"
March 27: Carlos Lllumiguano MD: Ecuador Neurosurgeon: "Pituitary Tumors: Surgical Indications"